ATH shareholder newsletter January 2025
Released
Released
Announcement PDF
Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline
Advances and Key Upcoming Milestones
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 January 2025: Alterity Therapeutics
(ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated
to developing disease modifying treatments for neurodegenerative diseases, has released a
Shareholder Newsletter.
You can access the full newsletter in this link: https://mailchi.mp/we-worldwide/alteritytherapeutics-shareholder-newsletter-january-2025
Below is an excerpt of the newsletter, a Letter to Shareholders from CEO David Stamler:
Dear Valued Shareholders:
As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity
Therapeutics.
I want to express my sincere gratitude for your unwavering support and belief in our mission to
develop disease-modifying therapies for those living with neurodegenerative diseases. Your
investment in Alterity allows us to pursue groundbreaking research and bring hope to patients
and families affected by these devastating conditions.
2024 was a year of significant progress for Alterity. Most prominently, we completed our 12month, double-blind Phase 2 clinical trial of ATH434 in early-stage Multiple System Atrophy
(MSA). This milestone leads us to a topline data readout expected in late January or early
February. Last July, we were pleased to report encouraging preliminary results from our openlabel biomarker study in individuals with more advanced MSA.
The preliminary results from the open-label study showed that individuals receiving 6-months
treatment with ATH434 had stable or improved clinical measures and that this clinical benefit
was supported by biomarker data: stable iron levels and brain volumes in clinical responders and
reduced neuronal injury compared to untreated patients from our MSA natural history study.
Taken together, these data provide strong support for the potential of ATH434 to slow the
progression of this very aggressive disease.
In addition to our advancements in clinical studies, we also continue to generate compelling data
in MSA and other neurological diseases. Last year, we presented promising preclinical data
demonstrating the potential of ATH434 in a primate model of Parkinson's disease. Our bioMUSE
Natural History study, in collaboration with Professor Daniel Claassen’s neuroimaging group at
Vanderbilt University Medical Center, yielded valuable insights into MSA progression and led to
the development of a novel imaging biomarker for assessing brain volume in regions affected by
MSA.
This year promises to be pivotal for Alterity with topline data expected from both of our Phase
2 clinical trials in MSA. Our team remains steadfast in their dedication to advancing our research
and development efforts and bringing innovative therapies to patients with neurodegenerative
diseases.
Thank you for your continued interest and support and we look forward to keeping you updated
on our progress.
David Stamler, M.D., Chief Executive Officer of Alterity.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has
the potential to treat various Parkinsonian disorders and is currently being evaluated in two
Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery
platform generating patentable chemical compounds to treat the underlying pathology of
neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s web site at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of
the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company
has tried to identify such forward-looking statements by use of such words as "expects,"
"intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and
other similar expressions, but these words are not the exclusive means of identifying such
statements.
Important factors that could cause actual results to differ materially from those indicated by
such forward-looking statements are described in the sections titled “Risk Factors” in the
Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as
reports on Form 6-K, including, but not limited to the following: statements relating to the
Company's drug development program, including, but not limited to the initiation, progress and
outcomes of clinical trials of the Company's drug development program, including, but not
limited to, ATH434, and any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval,
production and marketing of the Company’s drug components, including, but not limited to,
ATH434, the ability of the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug
compounds, including, but not limited to, ATH434, that could slow or prevent products coming
to market, the uncertainty of obtaining patent protection for the Company's intellectual
property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information
currently available to us and speaks only as of the date on which it is made. We undertake no
obligation to publicly update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information, future developments or
otherwise.
Share your feedback
Discover